The company said Imfinzi and chemotherapy, with or without tremelimumab, extended progression-free survival in first-line non-small cell lung cancer versus chemotherapy, setting up Imfinzi as a potential competitor to Merck's Keytruda. Overall survival data are expected next year.
The company said Wednesday that the pairing of PD-L1 inhibitor Imfinzi and CTLA-4 inhibitor tremelimumab did not prolong overall survival in previously untreated metastatic non-small cell lung cancer. The Phase III results are the latest in a string of failures for the combination.
Discover Houston's best orthopedic surgery centers and what features — from personalized treatment plans to rehabilitation services — make these top providers stand out in their industry.
The studies - in lung and head and neck cancers - produced negative results late last year. Several Phase I Imfinzi and tremelimumab studies were also removed, but others were added to the company's pipeline.
The company pointed to better survival numbers in patients with high tumor mutational burden, in a presentation at the ESMO immuno-oncology congress in Geneva.
Results of the Phase III EAGLE study leave Merck's Keytruda and Bristol's Opdivo as the dominant players in the space of HNSCC after progression on platinum-based chemotherapy.
Data from the Phase III MYSTIC study showed Imfinzi and tremelimumab did not extend survival in first-line NSCLC. AstraZeneca's shares were down on the news.
The layout of your phlebotomy station can significantly impact efficiency. A well-thought-out setup ensures that every tool is within reach, minimizing unnecessary movement and reducing patient wait times.